The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-11. Anything still debated is marked as such rather than presented as settled.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
==== X-ray intensifier foils ==== In the same year as the discovery of X-rays, Mihajlo Idvorski Pupin (1858-1935) invented the method of placing a sheet of paper coated with fluorescent substances on the photographic plate, drastically reducing the exposure time and thus the radiation exposure. 95% of the film was blackened by the intensifying film and only the remaining 5% was directly blackened by the X-rays. Thomas Alva Edison identified the blue-emitting calcium tungstate (CaWO4) as a suitable phosphor, which quickly became the standard for X-ray intensifying film. In the 1970s, calcium tungstate was replaced by even better and finer intensifying films with rare earth-based phosphors (terbium-activated lanthanum oxybromide, gadolinium oxysulfide). The use of intensifying films in dental film production did not become widespread because of the loss of image quality. The combination with high-sensitivity films further reduced radiation exposure.
== Metal coordination == Being a type of molecules that are often only activated for biological and chemical function following metal-binding, the specific coordination of metal ions imposes certain restrictions and requirements onto metallopeptides. Usually metal cofactors are coordinated by nitrogen, oxygen or sulfur centers belonging to amino acid residues of the peptide. These donor groups can be introduced by histidine (or the corresponding imidazole), cysteine (thiolate group), as well as carboxylate substituents (e.g. by aspartate) but are not limited to these. The other amino acid residues, including non-natural amino acids and the peptide backbone have been shown to bind metal centers and provide donor groups. The research on metal-binding of peptides ranges from coordination of biometals (such as Calcium, Magnesium, Manganese, Zinc, Sodium, Potassium, and Iron) to heavy metals (such as Arsenic, Mercury, and Cadmium).
GRMF affects primarily the liver (rather than the kidneys) for some physiological processes. High-potassium media (which stimulates aldosterone secretion in vitro) also stimulate cortisol secretion from the fasciculata zone of canine adrenals—unlike corticosterone, upon which potassium has no effect. Potassium loading also increases ACTH and cortisol in humans. This is probably the reason why potassium deficiency causes cortisol to decline (as mentioned) and causes a decrease in conversion of 11-deoxycortisol to cortisol. This may also have a role in rheumatoid-arthritis pain; cell potassium is always low in RA. Ascorbic acid presence, particularly in high doses has also been shown to mediate response to psychological stress and speed the decrease of the levels of circulating cortisol in the body post-stress. This decline can be evidenced through a decrease in systolic and diastolic blood pressures and decreased salivary cortisol levels after treatment with ascorbic acid.
Sources: en.wikipedia.org
=== Medium-lived fission products === After several years of cooling, most radioactivity is from the fission products caesium-137 and strontium-90, which are each produced in about 6% of fissions, and have half-lives of about 30 years. Other fission products with similar half-lives have much lower fission product yields, lower decay energy, and several (151Sm, 155Eu, 113mCd) are also quickly destroyed by neutron capture while still in the reactor, so are not responsible for more than a tiny fraction of the radiation production at any time. Therefore, in the period from several years to several hundred years after use, radioactivity of spent fuel can be modeled simply as exponential decay of the 137Cs and 90Sr. These are sometimes known as medium-lived fission products. Krypton-85, the 3rd most active MLFP, is a noble gas which is allowed to escape during current nuclear reprocessing; however, its inertness means that it does not concentrate in the environment, but diffuses to a uniform low concentration in the atmosphere. Spent fuel in the U.S. and some other countries is not likely to be reprocessed until decades after use, and by that time most of the 85Kr will have decayed.
Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was studied by Pfizer as a potential treatment of metabolic disorders such as type 2 diabetes mellitus. Its development was terminated in 1999.
=== Hostage-taking === According to the Human Rights Watch, the Houthis also use hostage taking as a tactic to generate profit. Human Rights Watch documented 16 cases in which Houthi authorities held people unlawfully, in large part to extort money from relatives or to exchange them for people held by opposing forces.
Sources: en.wikipedia.org
== Health effects == Due to the elevated levels of nitrites, consuming salted fish increases risk of stomach cancer and nasopharyngeal cancer. The International Agency for Research on Cancer classify salted fish (Chinese-style) as a Group 1 carcinogen.
==== Hypoglycemic glucagon impairment ==== Glucagon secretion is normally increased upon falling glucose levels, but normal glucagon response to hypoglycemia is blunted in type 1 diabetics. Beta cell glucose sensing and subsequent suppression of administered insulin secretion is absent, leading to islet hyperinsulinemia which inhibits glucagon release. Autonomic inputs to alpha cells are far more important for glucagon stimulation in the moderate to severe ranges of hypoglycemia, yet the autonomic response is blunted in several ways. Recurrent hypoglycemia leads to metabolic adjustments in the glucose-sensing areas of the brain, shifting the threshold for counterregulatory activation of the sympathetic nervous system to lower glucose concentration. This is known as hypoglycemic unawareness. Subsequent hypoglycemia is met with impairment in the sending of counter-regulatory signals to the islets and adrenal cortex. This accounts for the lack of glucagon stimulation and epinephrine release that would normally stimulate and enhance glucose release and production from the liver, rescuing the diabetic from severe hypoglycemia, coma, and death. Numerous hypotheses have been produced in the search for a cellular mechanism of hypoglycemic unawareness. A consensus has yet to be reached. The major hypotheses are summarized in the following table:
Qullqa's were generally built of masonry in connected groups on dry hillsides to take advantage of drainage and winds. Their size and design varied from region to region, but round qullqas were typically used to store maize and rectangular qullqas were used to store freeze-dried potatoes ("chuño") and other root crops. Qullqas had a ventilation system consisting of a channel beneath the floor to permit air to enter and an opening under the roof to allow air to escape. The interior diameter of an average small qullqa was 3.23 metres (10.6 ft); larger qullqas have a diameter of around 3.5–4.0 metres (11.5–13.1 ft). These smaller qullqa could have held 3.7 cubic metres (100 US bushels) of maize, and larger qullqa could have held about 5.5 cubic metres (160 US bushels) of maize. Most of the remains of qullqas near Cuzco have disappeared due to urban expansion and development over the centuries. The largest remaining number of qullqas is in the Mantaro River valley between the present days cities of Huancayo and Jauja, Peru. This broad valley, some 60 kilometres (37 mi) long contains about 65,000 hectares (160,000 acres) of cultivatable lands ranging in elevation from 3,200 metres (10,500 ft) to 4,250 metres (13,940 ft), the highest elevation at which cultivation was possible in this area. The Mantaro Valley was one of the largest and most fertile high-altitude areas of the Inca Empire. 2,573 qullqas have been found in the valley by archaeologists.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.